MAVS and Sepsis: In translational research: (1) Systematic evaluation of miR-27b’s safety, efficacy, and administration routes as a therapeutic target is lacking; (2) Specific drug intervention strategies targeting the Mff-MAVS axis have not been established; (3) The synergistic effects of miR-27b with existing sepsis treatment regimens and its differential effects in various pathological SCM subtypes remain unexplored; (4) Preclinical validation data in large animal models is lacking, limiting direct translational value for clinical applications.